The primary objective is to determine the safety and feasibility of administering R-MVST
cells to patients with refractory viral reactivation and/or symptomatic disease caused by
Epstein Barr Virus (EBV), cytomegalovirus (CMV), adenovirus (ADV) or BK virus. R-MVST cells
will be generated on-demand from the closest partially human leukocyte antigen (HLA)-matched
(minimum haploidentical) healthy donors or from the original allo-transplant donor if
available. The investigator will closely monitor the recipients for potential toxicities
including graft-versus-host disease (GVHD) post-infusion.
Secondary objectives are to determine the effect of R-MVST infusion on viral load, possible
recovery of antiviral immunity post-infusion and for evidence of clinical responses and
overall survival. Recipients will be monitored for secondary graft failure at day 28 post
R-MVST infusion.